<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280278</url>
  </required_header>
  <id_info>
    <org_study_id>5010010</org_study_id>
    <nct_id>NCT02280278</nct_id>
  </id_info>
  <brief_title>Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy</brief_title>
  <official_title>The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize through this randomized, prospective, single center adjuvant study, that&#xD;
      cytokine-induced killer cell in patients with stage III colon cancer can improve survival in&#xD;
      this patient population over control. Stage III colon cancer patients can benefit most from&#xD;
      adjuvant chemotherapy, but the 5 year survival rate is still around 60%. We wish CIK cell&#xD;
      therapy can improve the survival rate of stage III colon cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxin-side effect</measure>
    <time_frame>1 year</time_frame>
    <description>Toxin-side effect will be assessed by laboratory test, clinicians and questionary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Stage III Colon Cancer</condition>
  <arm_group>
    <arm_group_label>CIK group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical surgery</intervention_name>
    <arm_group_label>CIK group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <arm_group_label>CIK group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine-induced killer cell immunotherapy</intervention_name>
    <arm_group_label>CIK group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female outpatient of ≥ 18 years of age or ≥ country's legal age for adult&#xD;
             consent&#xD;
&#xD;
          -  Stage III colon cancer&#xD;
&#xD;
          -  undergone complete resection of primary tumor&#xD;
&#xD;
          -  Completed standard adjuvant chemotherapy&#xD;
&#xD;
          -  within 120 days of completion of standard therapy&#xD;
&#xD;
          -  ECOG performancer status 0-2&#xD;
&#xD;
          -  Satisfactory haematological or biochemical functions (tests should be carried out&#xD;
             within 8 weeks prior to randomisation): Results of clinical investigations carried out&#xD;
             within 8 weeks prior to randomisation can be used in place of the required screening&#xD;
             investigations. Patients with mild laboratory abnormalities can be included at the&#xD;
             discretion by the site principal investigator, and after approval by ASCOLT Trial&#xD;
             Management Group&#xD;
&#xD;
          -  ANC ≥ 1.0 x 109/L&#xD;
&#xD;
          -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤ 2.0 x the upper limit normal&#xD;
&#xD;
          -  AST &amp; ALT ≤ 5 x the upper limit normal&#xD;
&#xD;
          -  Completed the following investigations&#xD;
&#xD;
          -  Completed the following investigations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive or other Immunodeficiency disease&#xD;
&#xD;
          -  recently use of high dose glucocorticoid&#xD;
&#xD;
          -  Uncontrolled hypertension (untreated systolic blood pressure &gt; 160 mmHg, or diastolic&#xD;
             blood pressure &gt; 95 mmHg)&#xD;
&#xD;
          -  History of recent cancers (except for colorectal cancers, non-melanoma skin cancers,&#xD;
             basal cell carcinomas, squamous cell carcinomas) in the past 5 years&#xD;
&#xD;
          -  Patient having known allergy to capecitabine or Oxaliplatin&#xD;
&#xD;
          -  Pregnant, lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jun Wu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Jun Wu, Prof.</last_name>
    <phone>+86 20 87343456</phone>
    <email>wuxj@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>De-Sen Wan, Prof.</last_name>
    <phone>+86 20 87343456</phone>
    <email>wands@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guagzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong-Xin Zhang, Doc.</last_name>
      <phone>+86 20 87343456</phone>
      <email>zhangrx@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiao-Shi Zhang, Doc.</last_name>
      <phone>+86 20 87343456</phone>
      <email>zhangxs@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiao-Jun Wu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong-Xin Zhang, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhi-Zhong Pan, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao-Shi Zhang, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian-Chuan Xia, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan-Dan Li, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gong Chen, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhen-Hai Lu, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Jing Fang, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Heng Kong, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Zhong Lin, Doc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiao-Jun Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>cytokine-induced killer cell immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

